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Preservation of residual kidney function (RKF) is a relevant objective in peritoneal dialysis (PD) patients. 
The influence of dietary protein intake (PI) on this variable has not been adequately investigated. 
 
Methods 
Following an observational design, we studied 336 patients incident on PD, with a minimum follow-up of 
6 months. The main study variable was the mean PI [normalized rate of protein nitrogen appearance (nPNA)] 
during the first 4 months on PD. The main outcome variables were the absolute rate of decline of RKF and 
the proportion of patients presenting a >50% decay of their RKF during the first year of follow-up. We 
applied univariate and multivariate strategies of analysis, taking into consideration the main control variables 
bearing a correlation with nPNA and/or RKF. 
 
Results 
Mean nPNA (first 4 months) was 1.23 ± 0.33 g/kg/day, while the overall rate of decline of RKF was 
−0.13 ± 0.29 mL/min/month; 69 patients (25.1%) had lost >50% of their initial RKF by the end of the first 
year. Univariate analysis disclosed consistent associations between the main study variable on one hand and 
baseline RKF (r = 0.32, P < 0.0005) and its rate of decline (r = −0.23, P < 0.0005) on the other. The latter two 
variables were also significantly correlated (r = −0.36, P < 0.0005). Multivariate analysis identified mean 
nPNA as an independent predictor of the rate of decline of RKF [odds ratio 1.09 per 0.10 g/kg/day, 95% 
confidence interval (CI) 0.99–1.19, P = 0.058] and, in particular, of the probability of losing >50% of the 




Higher rates of PI during the first months of therapy are associated with a faster decline of RKF among 
patients incident on PD. Our results underline the convenience of keeping an adequate balance between 
sufficient protein ingestion, to prevent malnutrition and wasting, and sensible restriction in stable, adequately 
nourished individuals with rates of intake in the higher range or above-recommended allowances. 
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Introduction 
Malnutrition represents a feared complication of chronic kidney disease (CKD), due to its 
significant prevalence and detrimental impact on the outcome of affected individuals. Current 
recommendations for the management of patients at different stages of CKD pay particular 
attention to the prevention and treatment of this complication [1]. 
 
Maintaining an adequate protein intake (PI) is an essential step in the management of patients 
with CKD. This measure permits prevention of malnutrition, and may help to mitigate the negative 
effects of protein-energy wasting, a multifactorial complication frequently present in these subjects 
[2, 3]. However, it has long been known that dietary protein may also exert some negative effects 
on CKD patients, including an increase in uraemic toxicity and a potentially faster decline of 
residual kidney function (RKF) [4, 5]. As a consequence, dietary recommendations have been 
traditionally different for patients at different stages of CKD. For those not yet on dialysis therapy 
(in whom prevention of progression of CKD is a priority), moderate restriction of PI is endorsed 
by a majority of studies [6–9]. On the contrary, a more liberal PI is usually allowed to patients 
undergoing renal replacement therapy [10, 11], in the belief that dialysis is a catabolic condition 
demanding a reinforced nutritional support, that protein-induced uraemic toxicity can be controlled 
with an adequate dosing of dialysis and that RKF may not be as relevant as in patients on 
conservative treatment. However, the latter view has been challenged during the last two decades, 
for at least two reasons. First, a variable proportion of dialysis patients maintain relatively high 
rates of PI, often exceeding current recommendations [12, 13]. The balance between the benefits 
and disadvantages of ‘protein indulgence’ in this setting is largely undetermined. Secondly, 
nephrologists have become progressively aware of the clinical advantages of preserving RKF in 
patients treated with either haemodialysis [14] or peritoneal dialysis (PD) [15]. These 
considerations raise the hypothesis that high rates of PI may not be particularly beneficial for 
dialysis patients, and may accelerate the decline of RKF, with detrimental consequences for their 
outcomes. This hypothesis has not been thoroughly investigated. 
 
We present the results of a longitudinal study, oriented to disclose the potential effects of 
estimated PI during the first months of treatment on the rate of decline of RKF, in a relatively 
large sample of patients started on PD therapy. 
Materials and methods 
General design 
Following a retrospective, observational design, we undertook a study oriented to disclose the 
potential influence of estimated mean PI during the first 4 months of treatment with chronic PD 
(main study variable) on the rate of decline of RKF (main outcome) of a relatively large sample of 
patients incident on PD in our centre during the period 2000–16. PI was estimated from the urea 
kinetic-based protein equivalent of urea nitrogen appearance (nPNA), while RKF was estimated 
from the mean of renal urea and creatinine clearances. We applied both univariate and multivariate 
strategies of analysis to control the confounding effect of other factors with a potential influence 
on the main study outcome. 
 
This study fulfilled the ethic requirements of our centre for observational, retrospective studies. 
Oral informed consent was requested from patients, when feasible. The study complied with the 
principles of the Declaration of Helsinki for medical research. 
Study population 
We considered for analysis all adult (>18 years) patients starting PD therapy in our Unit during 
the period 2000–16, under five main inclusion criteria: 
 
i. at least one estimation of PI (nPNA) under stable clinical conditions during the first 4 
months on PD; 
ii. RKF ≥2 mL/min at the inception of PD; 
iii. a minimum follow-up of 6 months on PD; 
iv. estimations of RKF available, at least, at the start of PD and 6 ± 1 months after initiation 
of therapy; and 
v. oral informed consent for participation in the study (if patient still accessible). 
 
The following exclusion criteria were applied: 
 
i. denial of consent for participation in the study; 
ii. patients incident on PD after receiving haemodialysis therapy for >2 months; 
iii. patients incident on PD after renal transplant failure; and 
iv. patients in whom control variables considered essential for the analysis [age, gender, 
presence of diabetes, Charlson’s comorbidity score, basic anthropometrics (weight, 
height), proteinuria, treatment with antagonists of the renin–angiotensin–aldosterone axis 
(angiotensin-converting enzyme inhibitors-angiotensin-II receptor antagonists, ACEI-
ARA)] could not be retrieved. 
Study variables 
The main study variable was the mean of nPNA values recorded during the first 4 months on 
PD. By definition, all patients had at least one estimation, 283 (84.2%) had two and 182 (54.2%) 
had three estimations, during this period. Values obtained <1 month after the resolution of a 
significant clinical event (including peritoneal infection) were not considered for analysis. nPNA 
values were obtained using a standard software (PD Adequest, Baxter Healthcare, Deerfield, IL, 
USA) [16]. This software normalizes PI according to current body weight. For this reason, we 
renormalized PNA values to the ideal body weight of the patients. For this purpose, we first 
calculated the baseline dry weight of the patients as current body weight minus absolute 
overhydration, when this parameter was available (n = 202) (multifrequency bioimpedance device, 
BCM, Fresenius, Bad Homburg, Germany); in the remaining cases, we applied an estimated value 
of +1.35 L (mean of available estimations). Then, ideal body weight was calculated according to 
the Hamwi method [17]. 
 
The main outcome variable was the rate of decline of RKF (mean of urea and creatinine 
clearances, normalized to body surface area). This variable was managed in two different ways. 
 
i. Absolute variation of RKF: baseline minus last estimation available (with a limit at 24 
months), divided by the number of months of follow-up between the applied values (rate 
of decline of RKF, in mL/min/month). For this purpose, we recorded follow-up 
estimations of RKF at baseline (n = 336, 100%), 6 (n = 336, 100%), 12 (n = 275, 81.8%) 
and 24 months (n = 175, 52.1%). For multivariate analysis, this variable was categorized 
according to its median value. 
ii. Proportion of patients presenting a decline >50% of RKF after 12 months of follow-up 
(versus baseline). Expectedly, only patients with a minimal follow-up of 1 year (n = 275) 
were included for this part of the analysis. We renounced to our initial intention to apply 
development of anuria as an alternative outcome, because only 27 patients (8.0%) 
presented such complication during follow-up, preventing a consistent statistical 
management. 
For both nPNA and RKF, the term ‘baseline’ refers to the first adequacy assessment, routinely 
performed in our Unit 2–4 weeks after initiation of PD. 
 
We collected the following control variables at baseline: age, gender, presence of diabetes, 
standard Charlson’s comorbidity score, body mass index (dry body weight/height2), blood 
haemoglobin, plasma albumin, plasma C-reactive protein, proteinuria, modality of PD (at 6 
months), use of icodextrin for long dwell (baseline), use of biocompatible [low-glucose 
degradation products (GDP)] solutions, D/P 240′ creatinine [first peritoneal equilibration test 
(PET)], and treatment with ACEI-ARA drugs (any time during the first 6 months). Blood pressure 
(BP) levels were calculated from the mean values recorded during the first 2 months on PD 
therapy (in our unit, patients are instructed to record this parameter daily). Finally, we recorded 
episodes of peritoneal infection occurring during the period of follow-up of RKF. 
 
Urea and creatinine levels in blood, urine and spent dialysate were calculated with the help of a 
standard autoanalyzer. The same applied for haemoglobin and albumin levels. C-reactive protein 
levels were estimated by immunoturbidimetry. Proteinuria was estimated using a standard 
pyrogalol red procedure. 
Statistical analyses 
Basic comparisons were produced according to standard parametric (Student’s t-test, analysis 
of variance) and nonparametric tests (Mann–Whitney, Kruskall–Wallis, χ2 distribution, Fisher’s 
exact test, Spearman’s correlation coefficient), as needed. Univariate analyses focused on 
exploring the main correlates of mean nPNA during the first 4 months on PD, baseline RKF and its 
rate of decline. We then applied multivariate strategies of analysis to disclose any adjusted 
correlations between mean nPNA during the first 4 months on PD, on one side, and (i) the rate of 
decline of RKF during a follow-up period of 6 (minimum) to a limit of 24 months or (ii) the 
probability of a decline >50% of RKF after 1 year of follow-up, on the other. We did not consider 
the decline of RKF beyond 24 months due to the growing risk of selective biases brought by 
accumulating PD drop-out events. We used stepwise logistic regression to produce these analyses 
(dependent variables: rate of decline of RKF faster than median, and decline of RKF >50%, 1 year 
versus baseline). nPNA was managed as a continuous variable for the main multivariate analyses, 
but was secondarily categorized for a better clinical interpretation, into three levels, namely <1.00 
[low PI (LPI)] (n = 70), 1.00–1.40 [average PI (API)] (n = 162) and >1.40 g/kg/day [higher PI 
(HPI)] (n = 104). We censored patients for further data collection in the following cases: death, PD 
stopped for >1 month for any reason, loss to follow-up and 2-year follow-up completed. The SPSS 
19.0 software was used for data analyses. 
Results 
We included 336 patients for data analysis. The main characteristics of the study population are 
presented in Table 1. Diabetic nephropathy was the most frequent cause of CKD (n = 94, 28.0%), 
followed by chronic glomerulonephritis (n = 69, 20.6%), renal vascular disease (n = 51, 15.2%), 
cystic disorders (n = 26, 7.7%), tubulointerstitial disease (n = 21, 6.4%) and systemic conditions 
(including paraproteinemias) (n = 13, 3.8%). The aetiology of CKD was unknown in 62 cases 
(18.3%). Estimations of nPNA during the first 4 months correlated significantly (r = 0.65 baseline 
versus second estimation, P < 0.0005, Spearman), with a slight, yet significant trend to a decrease, 
during this period (1.24 baseline versus 1.21 g/kg/day second estimation, P = 0.023, paired t-test). 
 
  
Table 1. Study population: baseline characteristics 
N  336  
Age (years)  59.3 (14.9)  
Female gender (%)  116 (34.5)  
Diabetes (%)  127 (37.8)  
Charlson’s comorbidity score  3.7 (1.8)  
Automated PD at 6 months (%)  70 (21.0)  
Icodextrin (%)  162 (48.2)  
Low GDP solutions (%)  144 (42.9)  
Overhydration (L) (n = 202)  1.35 (1.67)  
Mean BP (mmHg)  96.7 (10.9)  
ACEI-ARA drugs (%)  113 (33.6)  
RKF (mL/min/1.73 m2)  7.9 (3.2)  
Proteinuria (g/day)  1.65 (1.77)  
D/P 240′ creatinine (PET)  0.68 (0.14)  
Plasma albumin (g/L)  36.7 (5.6)  
Serum C-reactive protein (mg/dL)  0.46 (0.01–17.8)  
Blood haemoglobin (g/dL)  10.9 (1.5)  
Body weight (kg)  70.9 (11.9)  
Height (m)  1.64 (0.09)  
Body mass index (kg/m2)  26.4 (4.5)  
Ideal body weight (kg)  62.5 (10.0)  
Mean nPNA, first 4 months (g/kg/day)  1.23 (0.33)  
Number of patients with peritoneal 
infection during follow-up (%)  127 (37.8) 
Figures denote mean values (SD) for numerical variables  
(except C-reactive protein, presented as median with range) and n (%)  
for categorized variables. Data at baseline except modality of PD (at 6 months)  
and nPNA (mean of first 4 months). 
Univariate analyses 
nPNA 
Table 2 displays the univariate correlations among mean nPNA and the main control and 
outcome variables scrutinized. Male, older, overweight and comorbid patients presented 
significantly higher estimated PI rates. More interestingly, mean nPNA showed a direct correlation 





Figure 1. Univariate correlation between baseline RKF and mean nPNA during the first  
4 months on PD (Spearman’s correlation coefficient). 
 
 
Figure 2. Univariate correlation between mean nPNA during the first months on PD and the rate  
of decline of RKF (Spearman’s correlation coefficient). 
 
 




first 4 months Baseline RKF 
Rate of decline of 
RKF 
Age (years)  0.10 (0.09)  −0.01 (0.83)  0.03 (0.56)  
Female gender (ref. male)  −0.14 (0.015)  −0.08 (0.17)  0.01 (0.83)  
Diabetes (ref. no)  0.28 (0.0005)  0.05 (0.28)  −0.10 (0.056)  
Charlson’s comorbidity score  0.15 (0.01)  0.006 (0.91)  −0.05 (0.34)  
Modality of PD (ref. CAPD)  −0.06 (0.35)  −0.01 (0.85)  −0.04 (0.47)  
Icodextrin, baseline (ref. no)  0.06 (0.32)  −0.11 (0.035)  0.007 (0.89)  
Low GDP solutions (ref. no)  0.07 (0.24)  0.16 (0.011)  −0.14 (0.022)  
Overhydration, baseline (L) (n = 202)  0.06 (0.49)  −0.06 (0.32)  −0.11 (0.061)  
Mean BP, baseline (mmHg)  −0.08 (0.30)  −0.02 (0.77)  −0.13 (0.021)  
ACEI-ARA, baseline (%) (ref. no)  0.08 (0.20)  0.01 (0.80)  0.04 (0.46)  
Baseline RKF (mL/m)  0.32 (0.0005)  –  −0.36 (0.0005)  
Rate of decline of RKF (mL/min/month)  −0.23 (0.0005)  −0.36 (0.0005)  –  
Proteinuria, baseline (g/day)  0.22 (0.0005)  0.01 (0.83)  −0.19 (0.0005)  
D/P 240′ creatinine (baseline PET)  0.07 (0.25)  0.02 (0.71)  −0.05 (0.45)  
Plasma albumin (g/L)  0.05 (0.39)  0.30 (0.0005)  −0.05 (0.35)  
C-reactive protein (mg/dL)  −0.08 (0.19)  −0.13 (0.007)  0.03 (0.55)  
Haemoglobin (g/dL)  −0.03 (0.61)  0.03 (0.63)  0.025 (0.61)  
Body mass index (kg/m2)  0.25 (0.0005)  0.05 (0.38)  −0.11 (0.03)  
Peritoneal infection (ref. no)  0.03 (0.64)  −0.10 (0.08)  −0.04 (0.44)  
Figures denote Spearman’s correlation coefficients (P-value). For the rate of decline of RKF,  
negative coefficients denote faster decline. CAPD, continuous ambulatory peritoneal dialysis. 
RKF 
The mean rate of decline of RKF for the whole group was −0.13 ± 0.29 mL/min/month. 
Remarkably, 124 patients (37.1%) had a similar or improved RKF at the end of follow-up, when 
compared with baseline. The univariate correlates of baseline RKF and its ensuing rates of decline 
are presented in Table 2. Baseline RKF, proteinuria, mean BP levels, body mass index and mean 
nPNA were all direct univariate correlates of a faster decline of RKF, while diabetes and 
overhydration showed similar, non-significant trends. 
 
A total of 61 patients were not available for analysis of the fractional decline of RKF at 1 year, 
due to kidney transplant (n = 29), death (n = 10), PD drop out (n = 4) or unavailability of an 
estimation of RKF at 12 ± 1 months (n = 18). Table 3 compares the main study variables in the 
remaining patients, according to the fractional decline of RKF during the first year on PD. 
Multivariate analyses 
Rate of decline of RKF 
The results of multivariate, logistic regression analysis disclosed that, after controlling for the 
main determinants of decline of RKF, higher mean nPNA levels tended to be associated with a 
faster decline of RKF, close to statistical significance (P = 0.058) (Table 4). Baseline RKF was, by 
far, the most consistent predictor of its ensuing rate of decline, with a marked potential 
confounding effect on the association between nPNA and the outcome variable, due to its 
significant correlation with both variables (Table 2). 
 
When nPNA was categorized, patients with HPI showed non-significant trends to a faster 
decline of RKF than those with LPI [odds ratio (OR) 1.61, 95% confidence interval (95% CI) 
0.77–3.44, P = 0.20] and API (OR 1.72, 95% CI 0.96–3.18, P = 0.064), without apparent 
differences between LPI and API patients (OR 0.94, 95% CI 0.47–1.86, P = 0.85) 
Table 3. Univariate comparisons according to fractional decline of RKF during the first year on PD 
 Decline >50% Decline ≤50% P-value 
N  69  206    
Age (years)  59.0 (17.8)  60.4 (13.2)  0.54  
Female gender (%)  24 (34.8)  69 (33.5)  0.85  
Diabetes (%)  25 (36.2)  81 (39.3)  0.81  
Charlson’s comorbidity score  3.6 (1.8)  3.7 (1.8)  0.68  
Modality of PD (% automated)  17 (24.6)  37 (18.0)  0.24  
Icodextrin (%)  33 (47.8)  102 (49.8)  0.82  
Low GDP solutions (%)  49.4  36.5  0.023  
Overhydration (L) (n = 185)  1.50 (1.71)  1.26 (1.50)  0.28  
Mean BP (mmHg)  97.0 (10.7)  97.0 (10.2)  0.97  
ACEI-ARA drugs (%)  20 (29.0)  76 (36.9)  0.19  
Baseline RKF (mL/min/1.73 m2)  7.8 (3.4)  8.4 (3.3)  0.25  
Rate of decline of RKF (mL/min/month)  −0.36 (0.28)  −0.09 (0.19)  0.0005  
Proteinuria (g/day)  1.96 (2.03)  1.45 (1.40)  0.023  
D/P 240′ creatinine (PET)  0.68 (0.15)  0.68 (0.13)  0.95  
Plasma albumin (g/L)  35.7 (6.2)  37.2 (4.8)  0.087  
Serum C-reactive protein (mg/dL)  0.49 (0.10–14.20)  0.46 (0.03–17.80)  0.75  
Blood haemoglobin (g/dL)  10.6 (1.5)  11.0 (1.3)  0.048  
Body mass index (kg/m2)  26.6 (4.0)  27.1 (4.6)  0.40  
Mean of nPNA, first 4 months (g/kg/day)  1.31 (0.33)  1.21 (0.29)  0.032  
Peritoneal infection (ref. no)  38.8  36.8  0.77  
Figures denote mean values with standard deviation for numerical variables (except C-reactive protein, presented as median 
with range), and n (%) for categorized variables. 
Table 4. Predictors of the rate of decline of RKF: multivariate, logistic regression analysis 
 B OR 95% CI P-value 
Baseline RKF (per mL/min/1.73 m2)  0.26  1.29  1.17–1.43  0.0005  
Proteinuria (per g/day)  0.20  1.22  1.02–1.45  0.022  
Age (per year)  −0.02  0.98  0.96–1.00  0.055  
Mean BP (per mmHg)  0.02  1.02  1.00–1.04  0.048  
Mean nPNA (per 0.10 g/kg/day)  0.09  1.09  0.99–1.19  0.058  
Constant  −4.99  0.007    0.0005  
Best model: −2log likelihood 335.4, χ2 56.35, P < 0.001. Outcome variable: rate of decline  
of RKF faster than median. First-order interaction terms not significant. 
 
 
Fractional decay of RKF at the end of the first year on PD 
Mean nPNA and proteinuria were identified as the only independent predictors of a decay 
>50% of RKF at the end of the first year on PD (Table 5). In this case, baseline RKF did not reach 
statistical significance for such outcome, but was included in the final model due to its potential 
confounding effect. As expected, in this case the trend was to a lower risk of the outcome in 
patients started on PD with higher levels of RKF. 
 
After categorization of nPNA, patients with HPI showed clear trends to a faster decline of RKF 
than those with LPI (OR 2.14, 95% CI 0.93–5.38, P = 0.091) or API (OR 2.32, 95% CI 1.12–4.76, 
P = 0.023), again without apparent differences between LPI and API patients (OR 0.92, 95% CI 
0.39–2.20, P = 0.86). 
Table 5. Predictors of decline >50% of RKF at 1 year: multivariate, logistic regression analysis 
 B OR 95% CI P-value 
Baseline RKF (per mL/min/1.73 m2)  −0.09  0.92  0.82–1.02  0.11  
Proteinuria (per g/day)  0.16  1.18  1.02–1.42  0.028  
Mean nPNA (per 0.10 g/kg/day)  0.14  1.15  1.04–1.27  0.006  
Constant  −2.59  0.075    0.001 
Best model: −2log likelihood 284.3, χ2 13.62, P = 0.004. Outcome variable: rate of decline  
of RKF faster than median. Interaction term Proteinuria * Mean nPNA not significant. 
Discussion 
Restriction of PI has been a mainstay in the management of patients with CKD for several 
decades. The essential objectives of this measure are reducing the effects of uraemic toxicity, 
retarding the appearance and progression of some complications of the disorder, and, most 
remarkably, delaying the natural trend to a progressive decline of the glomerular filtration rate that 
characterizes most cases of CKD [5]. Many studies, some of them large randomized clinical trials, 
have provided variable degrees of support to the expected benefits of dietary protein restriction. 
Current perception indicates that former approaches based on very low protein diets may be 
counterproductive, particularly if not accompanied by ketoacid supplementation, as evidenced by a 
detrimental impact on patient survival [18]. Thus, moderate protein restriction represents now the 
most common approach, and is endorsed by current practice guidelines [1, 10]. However, the 
benefits of moderate protein restriction are still controversial [5, 19], because of contradictory 
reports (including several systematic reviews and metaanalyses) on the effects of this measure on 
progression of CKD and patient mortality [6–9]. Potential reasons for the discrepancies observed 
include differences among the populations involved in the studies, variable degrees of protein 
restriction, a relatively high incidence of non-compliance among patients participating in trials 
[5, 20] and, for more recent studies, a downplayed effect of protein restriction brought about by a 
reinforced implementation of complementary measures, including systematic prescription of 
ACEI-ARA drugs and improved control of acidosis and hyperphosphataemia [5, 18]. 
 
Current dietary recommendations for patients with CKD undergoing chronic dialysis 
emphasize the prevention and treatment of malnutrition and wasting [10, 11, 21]. On the contrary, 
preservation of RKF is not generally taken into consideration at the time of planning PI, despite 
the evidence linking this parameter to the outcome of haemodialysis [14] and, even more 
markedly, PD patients [15]. RKF at the initiation of PD, and even more its rate of decline, are 
consistent independent predictors of mortality and PD technique failure [22]. On the other hand, 
the results of some studies suggest that a moderate, sensible limitation of PI may facilitate 
management of dialysis patients, and does not appear to bear negative effects on their nutritional 
status or outcomes, if nutritionally compromised individuals are excluded [23, 24]. On the 
contrary, stringent restriction of PI may entail a significant risk of mortality in these patients [24]. 
 
There is a marked paucity of data on the influence of PI on the time course of RKF in patients 
undergoing PD. In an exploratory survey aiming to disclose clinical predictors of the rate of 
decline of RKF in 146 PD patients, Johnson et al. [25] did not identify PI (as estimated from 
dietary questionnaires) as one such predictor although, in a secondary analysis, the authors 
observed that patients with higher levels of this variable presented an increased incidence of anuria 
during follow-up. On the other hand, in a small clinical trial, Jiang et al. [26] randomized 60 
prevalent PD patients to one of: normal protein diet (1.0–1.2 g/kg/day), low protein diet (0.6–0.8 
g/kg/day) and low protein diet supplemented with keto acids. Patients were followed for up to 1 
year. Patients on a low protein-keto acid diet experienced a modest, yet significant slower decline 
of RKF, while there was no apparent difference between patients on a low versus normal protein 
diet. However, the practical estimated PI was very similar in the normal and low protein diet 
groups during follow-up, and the study may have been underpowered to uncover differences. 
 
Our study provides evidence that higher levels of nPNA during the first months on PD 
associate a faster decline of RKF, suggesting that values above 1.4 g/kg/day may be particularly 
detrimental for this outcome. This effect was more apparent when the decline of RKF was 
explored as a fraction of baseline values than when absolute rates of decline were used as the 
outcome variable. The explanation for this relative discrepancy is not totally clear, but residual 
confounding by baseline RKF may have contributed significantly. RKF at the inception of PD 
showed a marked correlation with the absolute rate of decline of RKF (Table 1), which agrees with 
previous reports [25, 27], but had a less apparent association with its proportional decline over 
time (Table 3). On the other hand, baseline RKF kept a significant correlation with baseline and 
mean nPNA during the first months on PD (Table 2, Figure 1), again confirming the results of 
previous studies [24, 28, 29]. It has been argued that this latter association may be partly a 
consequence of mathematical coupling, but RKF has shown a similar correlation with PI in CKD 
patients, when the latter is estimated from dietary questionnaires [14, 28–30]. 
 
Interestingly, categorization of nPNA showed more consistent differences in the rate of decline 
of RKF between HPI and API groups than between the HPI and LPI groups. This finding should 
not be in contradiction to our main contention that excess PI may be detrimental for the rate of 
decline of RKF. Spontaneously low PI rates may mark specific subsets of patients who, for 
different reasons, may also tend to have an accelerated decline of RKF, downplaying any putative 
beneficial effect of restricted PI. On the other hand, the unequal size of the LPI, API and HPI 
groups may also have influenced statistical comparisons. We preferred to classify PI rates with a 
clinical meaning, rather than using a more conventional categorization by tertiles. 
 
The present analysis posed some relevant methodological challenges. We acknowledge that, 
for some of them, we undertook debatable decisions. We did not apply time-dependent analysis to 
explore longitudinally the effect of nPNA, in the belief that the natural decline of RKF could itself 
bring about a progressive decay of PI. We censored follow-up for RKF at 2 years to minimize 
selective biases secondary to the rapidly growing incidence of PD drop out after this limit. It is 
conceivable that faster rates of decline of RKF could contribute to mortality and transfer to 
haemodialysis, in some of these cases. Another important issue is the convenience of normalizing 
nPNA to ideal body weight, which we applied to all our patients. Some guidelines consider 
compelling this correction only when the current dry weight is markedly lower (<90%) or higher 
(>115%) than ideal weight [1, 21]. This caution, neglected in some former studies, is very 
relevant, because normalization of PI to current body weight in undernourished, overweight or 
overhydrated individuals results in unrealistic estimations [12]. The advantages and drawbacks of 
different methods of standardization of PI have been reviewed in detail elsewhere [31]. 
 
In addition to the questions commented on in the previous paragraph, our study suffers some 
other significant limitations. These include a single-centre, retrospective design. Dietary surveys 
offer some advantages at the time of estimating PI, avoiding risks of mathematical coupling with 
some variables, but this method has also a limited accuracy, and urea kinetics is generally 
recognized as a reliable method to evaluate PI in stable CKD patients [4, 32] and, particularly, in 
PD patients [33, 34]. We cannot exclude that, in some of our patients, undetected catabolic states 
may have flawed part of the estimations of PI. The use of a mean of two to three nPNA values as 
the main study variable in the majority of cases should be expected to mitigate this potential bias. 
Isolated estimations of nPNA are unsuitable for evaluation of PI and guidance of dietary 
recommendations in individuals sustaining a suspected catabolic phase and, in general, in severely 
malnourished and comorbid patients. On the other hand, among the strengths of this study, we 
should mention a powered sample and a high quality and completeness of the main control 
variables, permitting consistent and reliable conclusions for the analyses performed. 
 
In conclusion, our study provides evidence that high rates of PI may associate a faster decline 
of RKF in patients starting PD. Our results suggest the convenience of keeping a balance between 
sufficient protein ingestion, to prevent malnutrition and wasting, and sensible restriction for stable, 
adequately nourished patients with rates of intake in the higher range or above-recommended 
allowances. Dietary education and close monitoring of PI by means of urea kinetics, dietary 
surveys or any other validated method represent adequate instruments, for these purposes. Further 
studies will be necessary to validate our results 
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